News
Expert: GLP-1 therapies for obesity
Published: 3 December 2025
The World Health Organization has issued on the use of GLP-1 therapies, such as Ozempic, to treat obesity, a chronic disease affecting more than 1 billion people worldwide and projected to double by 2030.
A Â鶹´«Ã½ÍøÕ¾ expert is available to comment:
, MD, is an Associate Professor in the Division of Endocrinology, Co-Director of the Metabolic Centre of Excellence at the Â鶹´«Ã½ÍøÕ¾ Health Centre (MUHC) and an Investigator at the Research Institute of the MUHC. He can discuss how GLP-1 therapies work, what the new guidelines mean for treatment access and clinical practice and emerging research on benefits beyond weight loss.
michael.tsoukas [at] mcgill.ca (English, French)
